1. Home
  2. RGLS vs LEE Comparison

RGLS vs LEE Comparison

Compare RGLS & LEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGLS
  • LEE
  • Stock Information
  • Founded
  • RGLS 2007
  • LEE 1890
  • Country
  • RGLS United States
  • LEE United States
  • Employees
  • RGLS N/A
  • LEE N/A
  • Industry
  • RGLS Biotechnology: Pharmaceutical Preparations
  • LEE Newspapers/Magazines
  • Sector
  • RGLS Health Care
  • LEE Consumer Discretionary
  • Exchange
  • RGLS Nasdaq
  • LEE Nasdaq
  • Market Cap
  • RGLS 102.1M
  • LEE 90.6M
  • IPO Year
  • RGLS 2012
  • LEE N/A
  • Fundamental
  • Price
  • RGLS $1.55
  • LEE $14.50
  • Analyst Decision
  • RGLS Strong Buy
  • LEE
  • Analyst Count
  • RGLS 6
  • LEE 0
  • Target Price
  • RGLS $10.33
  • LEE N/A
  • AVG Volume (30 Days)
  • RGLS 268.2K
  • LEE 32.7K
  • Earning Date
  • RGLS 11-07-2024
  • LEE 01-30-2025
  • Dividend Yield
  • RGLS N/A
  • LEE N/A
  • EPS Growth
  • RGLS N/A
  • LEE N/A
  • EPS
  • RGLS N/A
  • LEE N/A
  • Revenue
  • RGLS N/A
  • LEE $611,380,000.00
  • Revenue This Year
  • RGLS N/A
  • LEE $2.04
  • Revenue Next Year
  • RGLS N/A
  • LEE $0.21
  • P/E Ratio
  • RGLS N/A
  • LEE N/A
  • Revenue Growth
  • RGLS N/A
  • LEE N/A
  • 52 Week Low
  • RGLS $1.08
  • LEE $7.57
  • 52 Week High
  • RGLS $3.79
  • LEE $19.63
  • Technical
  • Relative Strength Index (RSI)
  • RGLS 49.06
  • LEE 41.79
  • Support Level
  • RGLS $1.49
  • LEE $13.33
  • Resistance Level
  • RGLS $1.62
  • LEE $15.14
  • Average True Range (ATR)
  • RGLS 0.11
  • LEE 0.93
  • MACD
  • RGLS -0.00
  • LEE -0.12
  • Stochastic Oscillator
  • RGLS 37.50
  • LEE 37.74

About RGLS Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

Share on Social Networks: